This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-08. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Dover's powder (a.k.a. pulvis ipecacuanhae et opii) was a medicine against cold and fever. Developed in 1732 by English physician Thomas Dover, the powder was an old preparation of powder of ipecacuanha (which was formerly used to produce syrup of ipecac), opium in powder, and potassium sulfate. Initially designed to treat gout, it was later recommended for general pains, insomnia, and diarrhea, among others. The powder was largely used in domestic practice to induce sweating, to defeat the advance of a common cold, and at the beginning of any attack of fever. It is no longer in use in modern medicine, but remained reputable until about the 1930s. Its inclusion of opium, an addictive substance, led to its discontinuation of use. Dover's powder was banned in India in 1994.
==== Lung ==== Extracorporeal membrane oxygenation (ECMO) machines, otherwise known as heart and lung machines, are an adaptation of cardiopulmonary bypass techniques that provide heart and lung support. It is used primarily to support the lungs for a prolonged but still temporary timeframe (1–30 days) and allow for recovery from reversible diseases. Robert Bartlett is known as the father of ECMO and performed the first treatment of a newborn using an ECMO machine in 1975. Skin Tissue-engineered skin is a type of bioartificial organ that is often used to treat burns, diabetic foot ulcers, or other large wounds that cannot heal well on their own. Artificial skin can be made from autografts, allografts, and xenografts. Autografted skin comes from a patient's own skin, which allows the dermis to have a faster healing rate, and the donor site can be re-harvested a few times. Allograft skin often comes from cadaver skin and is mostly used to treat burn victims. Lastly, xenografted skin comes from animals and provides a temporary healing structure for the skin. They assist in dermal regeneration, but cannot become part of the host skin. Tissue-engineered skin is now available in commercial products. Integra, originally used to only treat burns, consists of a collagen matrix and chondroitin sulfate that can be used as a skin replacement. The chondroitin sulfate functions as a component of proteoglycans, which helps to form the extracellular matrix.
=== Other characters === Toko Miura as Chiyoko Shimakura, a singer whose career becomes connected to Kazuko and Hotta. Yuko Nakamura as Mirei Sei, a fortune teller who influences Kazuko's later career. Shingo Mizusawa as a street vendor (episode 1). Hiccorohee as Mai (episode 1). Kimiko Yo as Kiyo Mita (episodes 2–3), Marohiko's mother and the head of the Mita household. Miwako Ichikawa as Towako Kato (episodes 8–9), Masataka Yasunaga's daughter. Show Kasamatsu as Osamu Miyazawa, Minori Uozumi's ex-husband (episode 8). Kaho Tsuchimura as a mistress (episodes 8–9). Toshie Negishi as Minori Uozumi's mother. Nagomu Miyamoto as Nobu Murao. Razor Ramon HG as himself
=== Brazil === Between 2005 and 2021, Brazil had 1,576 suspected cases of CJD, of which 547 were confirmed. In August 2026, Brazilian aviation expert Lito Sousa was diagnosed with CJD. He died two months later, on October 1.
Sources: en.wikipedia.org
Primary structure: the amino acid sequence. A protein is a polyamide. Secondary structure: regularly repeating local structures stabilized by hydrogen bonds. The most common examples are the α-helix, β-sheet and turns. Because secondary structures are local, many regions of distinct secondary structure can be present in the same protein molecule. Tertiary structure: the overall shape of a single protein molecule; the spatial relationship of the secondary structures to one another. Tertiary structure is generally stabilized by nonlocal interactions, most commonly the formation of a hydrophobic core, but also through salt bridges, hydrogen bonds, disulfide bonds, and even post-translational modifications. The term "tertiary structure" is often used as synonymous with the term fold. The tertiary structure is what controls the basic function of the protein. Quaternary structure: the structure formed by several protein molecules (polypeptide chains), usually called protein subunits in this context, which function as a single protein complex. Quinary structure: the signatures of protein surface that organize the crowded cellular interior. Quinary structure is dependent on transient, yet essential, macromolecular interactions that occur inside living cells. Proteins are not entirely rigid molecules. In addition to these levels of structure, proteins may shift between several related structures while they perform their functions.
Puillandre, N.; Meyer, C.P.; Bouchet, P.; Olivera, B.M. (2011). "Genetic divergence and geographical variation in the deep-water Conus orbignyi complex (Mollusca: Conoidea)". Zoologica Scripta. 40 (4): 350–363. doi:10.1111/j.1463-6409.2011.00478.x. PMC 3123138. PMID 21712968. Puillandre, N.; Duda, T.F.; Meyer, C.; Olivera, B.M.; Bouchet, P. (2015). "One, four or 100 genera? A new classification of the cone snails". Journal of Molluscan Studies. 81 (1): 1–23. doi:10.1093/mollus/eyu055. PMC 4541476. PMID 26300576. Puillandre, N.; et al. (2014). "Molecular phylogeny and evolution of the cone snails (Gastropoda, Conoidea)". Mol. Phylogenet. Evol. 78: 290–303. Bibcode:2014MolPE..78..290P. doi:10.1016/j.ympev.2014.05.023. PMC 5556946. PMID 24878223. Reeve L (1844). "Conchologia Iconica". Monograph of the genus Conus. Vol. 1. pp. 40–47. Sowerby, G. B., II. 1833. Conus. Conchological Illustrations pls. 36–37 Taylor, J. D.; Kantor, Yu. I.; Sysoev, A. V. (1993). "Foregut anatomy, feeding mechanisms, relationships and classification of Conoidea (Toxoglossa) (Gastropoda)". Bull. Nat. Hist. Mus. 59: 125–169. Tenorio MJ, Tucker JK, Chaney HW (2012). "The Families Conilithidae and Conidae. The Cones of the Eastern Pacific". In Poppe GT, Groh K (eds.). A Conchological Iconography. Hackenheim: ConchBooks. p. 112. Tucker J.K. & Tenorio M.J. (2009), Systematic Classification of Recent and Fossil Conoidean Gastropods, ConchBooks, Hankenheim, Germany, 295 pp. Van Mol JJ, Tursch B, Kempf M (1967). "Mollusques prosobranches: Les Conidae du Brésil.
In August 2020, British and American officials stated that the Gam-COVID-Vac vaccine would likely be rejected due to concerns that the normally rigorous process of vaccine clinical testing was not followed. As of December 2020, Belarus and Argentina granted emergency use authorization for the vector-based vaccine. On 21 January 2021, Hungary became the first European Union country to register the shot for emergency use, as well as the United Arab Emirates in the Persian Gulf region. On 19 January 2021, the Russian authorities applied for the registration of Sputnik V in the European Union, according to the RDIF. On 10 February, the European Medicines Agency (EMA) said that they had "not received an application for a rolling review or a marketing authorisation for the vaccine". The developers have only expressed their interest that the vaccine be considered for a rolling review, but EMA's Human Medicines Committee (CHMP) and the COVID-19 EMA pandemic Task Force (COVID-ETF) need to give their agreement first before developers can submit their application for initiation of the rolling review process. On 4 March 2021, the Committee for Medicinal Products for Human Use (CHMP) of the EMA started a rolling review of Sputnik V. The EU applicant is R-Pharm Germany GmbH, a subsidiary of the Russian R-Pharm. On 16 June, Reuters reported that approval of Sputnik V will be delayed at least until September because not all the necessary clinical data has been submitted by the deadline.
Sources: en.wikipedia.org
== Work == The new São Paulo Institute was built in a section of the city named Butantan, at the time a far-away place, near the Pinheiros river, a swampy, sparsely inhabited area. Under Vital Brazil, it soon became an energetic and exemplary research center in vaccines and sera of all kinds, which were produced locally for the prophylaxis and treatment of tetanus, diphtheria, yellow fever, smallpox and several zoonoses (diseases transmitted to humans by animals), such as the dreaded hydrophobia. The Institute came to be well known by his original name, the Butantan Institute, and is still active today. Vital Brazil was convinced since his early work at Butantan that envenomations (poisoning by accidents with venomous animals, such as snakes, scorpions, spiders and batrachia, then the cause of thousands of deaths in Brazil) could be fought with antisera, i.e., antibodies specifically produced for venoms which were proteins or long-chain peptides. A French immunologist, Albert Calmette (1863–1933) had demonstrated this for the first time in 1892, by developing a monovalent serum to treat bites by the Indian cobra (Naja tripudians).
While Neanderthals may have been using this process 200,000 years ago, the oldest evidence for dry distillation among modern humans only dates to 20,000 years ago. Many Neanderthal sites have evidence of fire, some for extended periods of time. They may have been using fire for cooking, keeping warm, and deterring predators. They were also capable of zoning areas for specific activities, such as for knapping, butchering, hearths, and wood storage. At Abric Romaní rock shelter, Spain, Neanderthals may have maintained eight evenly spaced hearths lined up against the rock wall, likely used to stay warm while sleeping, with one person sleeping on either side of the fire. The only known Neanderthal tools that could have been used to fashion clothes are hide scrapers as no bone sewing-needles and stitching awls have been found as in Cro-Magnon sites. Hide scrapers could have been used to make items similar to blankets or ponchos. There is no direct evidence that Neanderthals could make fitted clothes from animal hide. Unfitted clothes would have limited range of mobility while dressed, and decreased the time Neanderthals could spend unprotected from the elements away from shelters. Anterior dental microwear of Neanderthals living in open environments is similar to that of the modern Ipiutak and Nunavut people, who are known to use their anterior teeth for clamping while preparing hides, suggesting that Neanderthals may have engaged in similar behaviour.
Communication delays during the crisis led to the establishment of the Moscow–Washington hotline to allow reliable, direct communications between the two nuclear powers. By the late 1960s, the number of ICBMs and warheads was so high on both sides that it was believed that both the United States and the Soviet Union were capable of completely destroying the infrastructure and a large proportion of the population of the other country. Thus, by some western game theorists, a balance of power system known as mutually assured destruction (or MAD) came into being. It was thought that no full-scale exchange between the powers would result in an outright winner, with at best one side emerging the pyrrhic victor. Thus both sides were deterred from risking the initiation of a direct confrontation, instead being forced to engage in lower-intensity proxy wars. During this decade the People's Republic of China began to build subterranean infrastructure such as the Underground Project 131 following the Sino-Soviet split. One drawback of the MAD doctrine was the possibility of a nuclear war occurring without either side intentionally striking first. Early Warning Systems (EWS) were notoriously error-prone. For example, on 78 occasions in 1979 alone, a "missile display conference" was called to evaluate detections that were "potentially threatening to the North American continent". Some of these were trivial errors and were spotted quickly, but several went to more serious levels.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.